FLT3 and acute myeloid leukemia: Mutations of the FLT3 gene exist in about 30% of patients with AML, with 25% having the FLT3 internal tandem duplication (ITD) mutation and the other 5–10% presenting with the FLT3 tyrosine kinase domain (TKD) mutation, which lead ligand‐independent activating of the RTK and the downstream proliferative signaling pathways.246, 247